Dr. Abel Kho is an Internist and Professor of Medicine and Preventive Medicine in the Northwestern University Feinberg School of Medicine where he is the Founding Director of both the Center for Health Information Partnerships (2015) and the Institute for Augmented Intelligence in Medicine (2020). His research focuses on developing regional Electronic Health Record (EHR) enabled data sharing platforms for a range of health applications including high throughput phenotyping, cohort discovery, estimating population level disease burden, and quality improvement. He has served as Principal Investigator for over $80M in external funding, published over 100 manuscripts, and mentored numerous students and trainees. He is an internationally recognized expert in privacy preserving record linkage, having published the first large scale real-world application of this method for which he was assigned a patent, and cofounded a startup which was subsequently acquired by Datavant. He is an elected Fellow of the American College of Medical Informatics and recipient of the Donald A.B. Lindbergh Award for Innovation in Informatics.

Dr. Akshay Desai is the Director of the Cardiomyopathy and Heart Failure Program in the Advanced Heart Disease Section of the Cardiovascular Division, Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School (both in Boston, Massachusetts). He received his undergraduate education at Princeton University, where he graduated Summa Cum Laude in 1992 with an A.B. in Public and International Affairs. He was subsequently awarded a Rhodes Scholarship for study at Oxford University, where he completed an M. Phil. in European Politics and Society at Balliol College in 1994. Following on this, he began his medical training at Harvard Medical School where he was awarded the M.D. degree in 1998. He completed his internship and residency in Internal Medicine at Brigham and Women’s Hospital in 2001 and subsequently elected to pursue fellowship training in Cardiovascular Medicine at the same institution. During the final years of subspecialty training in cardiology, he completed additional fellowship training in Heart Failure and Transplantation under the direction of Dr. Lynne Stevenson. Concurrently, he conducted translational research in vascular medicine and diastolic heart failure under the supervision of Dr. Mark Creager. He was awarded an M.P.H. in 2004 from the Harvard School of Public Health. He currently divides his time between clinical care of patients with advanced heart disease and clinical research in cardiovascular clinical trials, with an emphasis on the pathophysiology, pharmacologic treatment, and ambulatory management of patients with heart failure.

Dr. Alain Bertoni trained at Johns Hopkins for his MD and MPH. He completed internal medicine residency at the Johns Hopkins Hospital. He is a board-certified general internist and epidemiologist whose primary research interests are in the areas of type 2 diabetes, metabolism, and obesity and their relationship to cardiovascular diseases, including heart failure. He has been at Wake Forest School of Medicine since 2001 and currently is Professor and Associate Director of Public Health Sciences. He has experience working on cohort studies (ARIC, Jackson Heart Study, and the Multi-Ethnic Study of Atherosclerosis (MESA)) as well as clinical trials. He is the current field center PI for MESA, and is a co-investigator for HeartShare, and the REHAB-HFpEF randomized trial.

Dr. Barry Borlaug is Professor of Medicine and Director of Circulatory Failure Research in the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, MN. He is an active clinical investigator interested in the fields of heart failure and pulmonary hypertension, with particular interest on the hemodynamic underpinnings of cardiac disease and exercise physiology. He is currently working to better understand the causes and mechanisms of heart failure and pulmonary vascular disease, and is active in a number of clinical trials developing and testing novel medical and device based therapies to improve outcomes for people with heart failure.

Dr. Dalane W. Kitzman is a Professor of Cardiovascular Medicine and Geriatrics/Gerontology at Wake Forest School of Medicine, and the Kermit G. Phillips II Endowed Chair in Cardiovascular Medicine. His career focus is understanding and treating the severe physical dysfunction associated with cardiovascular disease in older persons, particularly heart failure with preserved ejection fraction (HFpEF). He published one of the earliest descriptions of HFpEF and one of the first mechanistic phenotyping studies in the disorder. His work has contributed significantly to advancing our understanding of the pathophysiology and treatment of HFpEF, particularly the pivotal outcome of the severe exercise intolerance experienced by these patients. His team 34 reported the first randomized controlled trials of exercise training and dietary weight loss in HFpEF, which remain among the few proven interventions for exercise intolerance in HFpEF. Dr. Kitzman has received many awards for his original research, including the prestigious MERIT award from NIH, and the Michael L. Pollack Established Investigator Award from AACVPR. He has served in key/leadership positions for >30 clinical trials, most of them focused on HF, contributed to 5 large, NIH-funded population studies, and served on and chaired many NIH and other national committees. Dr. Kitzman is Associate Editor for JAGS and Consulting Editor for JACC:HF, has authored nearly 500 peer-reviewed publications, and successfully mentored ~30 early career investigators toward independence.

Dr. Denise Scholtens is Chief of the Division of Biostatistics and Director of Northwestern University Data Analysis and Coordinating Center (NUDACC). She is interested in the design and conduct of multicenter, prospective observational studies and clinical trials and serves as the data coordinating center director and lead statistician for multiple large-scale, ongoing studies. She is particularly interested in the integration of high-dimensional data analyses into these settings.

Dr. Faraz Ahmad is an Assistant Professor of Medicine-Cardiology and Preventive MedicineHealth and Biomedical Informatics and the Associate Director of the Bluhm Cardiovascular Institute Center for Artificial Intelligence at Northwestern Medicine. Dr. Ahmad’s research interests are in the application of data science and digital health technologies to improve quality of care and patient-centered outcomes for patients with heart failure and other cardiovascular diseases. His work has received support from multiple organizations, including the National Heart, Lung, and Blood Institute, the American Heart Association, the Patient-Centered Outcomes Research Institute, the Heart Failure Society of America, and the Centers for Disease Control and Prevention. Dr. Ahmad is a practicing heart failure cardiologist who cares for 27 patients across the spectrum of heart failure. He has a particular clinical interest in the diagnosis and management of patients with heart failure with preserved ejection fraction and with cardiac amyloidosis.

Dr. Javed Butler is the President of the Baylor Scott and White Research Institute and Senior Vice President for the Baylor Scott and White Health. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MS. Prior to joining Baylor Scott and White Health, he served as the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi, where he was also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that. He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and an MBA from the Emory University. Dr. Butler’s research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association. Dr. Butler has authored more than 875 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals. He has been cited numerous times in America’s Best Doctors list.

Dr. Jeff Olgin is Chief of Cardiology and the Gallo-Chatterjee Distinguished Professor of Medicine at UCSF. He is a practicing electrophysiologist and cardiologist and a cardiovascular 35 researcher. He has been involved in leading clinical trials and clinical research for over 30 years. He is one of the Principal Investigator of the Health eHeart Study and one of the creators and Principal Investigator of the Eureka Research Platform. In addition to basic research and clinical trials focused on arrhythmia mechanisms, prediction, detection and prevention, he has a robust research program in digital health and developing novel technology for digitally-enabled clinical research and trials.

Dr. Julio A. Chirinos is the Director of the Core Laboratory and an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine. Dr. Chirinos directs an established extramurally funded research program at Penn, focused on the non-invasive assessment of cardiac and arterial structure and function using a combination of imaging modalities (including echocardiography and cardiac MRI), in patients with or at risk for heart failure. The lab has particular expertise in assessing arterial stiffness and its impact on target organs, particularly the left ventricle. Dr. Chirinos also studies the effects of interventions to attenuate left ventricular hypertrophy, fibrosis and dysfunction. We have particular interest/experience in assessing the mechanistic effects of novel treatments for Heart Failure with Preserved Ejection Fraction. Dr. Chirinos has published over 150 scientific papers, chapters, reviews, and editorials. He has also participated in various working groups and guideline Committees for the American Heart Association, the European Society of Cardiology, the American Society of Hypertension, the American Society of Echocardiography, and the European Association of Cardiovascular Imaging.

Dr. Laura Rasmussen-Torvik is a genetic epidemiologist interested in the identification of genetic risk factors for chronic diseases and the implementation of genomics into clinical care. She is also interested in the use of electronic health records in clinical and epidemiological research. She has worked extensively with multiple large observational cohort studies including MESA and CARDIA. She is one of the PI of the Northwestern center of the NHGRI-32 funded eMERGE network which conducts genetic discovery and implementation research using biorepositories linked to electronic health record data.

Dr. Lauren Balmert-Bonner is an Assistant Professor in the Department of Preventive Medicine, Division of Biostatistics, whose research interests lie in clinical trial design and analysis, connecting methodological developments with clinical applications. As a member of the Biostatistics Collaboration Center (BCC) and Northwestern University Data Analysis and Coordinating Center (NUDACC), she facilitates and promotes scientific research as a collaborative biostatistician across a range of clinical fields including HIV maternal child health, gastroenterology, and pediatric medicine. She currently serves as the lead biostatistician forseveral studies: a cluster randomized trial assessing the effectiveness of a walking intervention on reducing frailty; a phase II pharmacodynamic study in patients with critical COVID19 pneumonia; and two concurrent trials comparing interventions for pediatric arm fractures. For the HeartShare Network, she serves as Data Management Core PI within the Data Translation Center.

Dr. Margaret Redfield is a heart failure cardiologist and has devoted her research career to the study of HFpEF epidemiology, pathophysiology and therapeutics in human subjects and animal models. She has performed large scale, prospectively enrolled, mechanistic cohort studies. Dr. Redfield designed and served as national PI on randomized clinical trials of therapy in HFpEF. Under her leadership, Mayo led enrollment in both funding cycles (12 years) of the NIHsponsored Heart Failure Clinical Research Network and proposed and led 5 of the trials (3 in HFpEF) performed in the Network. She has served on the scientific advisory board/steering committees for large industry-sponsored trials in HFpEF (PARAGON, CAPACITY). She has performed extensive studies of biomarkers in community and HF cohorts, studied inflammatory mediators in HFpEF, analyzed large complex data sets and used artificial intelligence to 31 discover HFpEF phenogroups. She has unique expertise in pathological studies on human and animal HFpEF tissues. More recently, Dr. Redfield has used mass spectroscopy-based proteomics and bioinformatics approaches to study mechanisms underpinning pulmonary arterial and pulmonary venous remodeling in HFpEF with pulmonary hypertension. She has served on the major HFpEF working groups, including the most recent NIH working group identifying the key research priorities in HFpEF.

Dr. Sadiya Khan received her medical degree from the Feinberg School of Medicine at Northwestern University in 2009 as part of the Honors Program in Medical Education. She completed her internship and residency in Internal Medicine at Northwestern University Feinberg School of Medicine in Chicago, IL in 2012 and then served as Chief Medical Resident from 2012-2013. She also obtained her master’s degree in Clinical Investigation from the Northwestern University Graduate School in 2014. Dr. Khan completed her fellowship in cardiovascular diseases at Northwestern in 2016 followed by a post-doctoral fellowship in cardiovascular epidemiology in 2017 before joining the Northwestern faculty. She has received multiple awards for excellence in research, teaching, and patient care.

Dr. Sanjiv J. Shah is the Stone Endowed Professor; Director of Research for the Bluhm Cardiovascular Institute; Director, Center for Deep Phenotyping and Precision Medicine in the Institute for Augmented Intelligence in Medicine; and Director of the HFpEF Program at Northwestern University Feinberg School of Medicine. Dr. Shah’s clinical expertise and research program are focused HFpEF, and in 2007, he started the world’s first dedicated HFpEF program at Northwestern University; this program has served as a model for several other similar programs in the United States and throughout the world. Dr. Shah has been continuously funded by grants from the AHA and the NIH since 2008. He directs a laboratory that investigates the pathogenesis of HFpEF; conducts multicenter clinical trials of novel therapeutics for heart failure, pulmonary hypertension, and cardiac amyloidosis; and develops novel techniques for machine learning and AI for the classification, diagnosis, and tracking of cardiovascular diseases. His research, which has spans basic research in animal models, clinical physiologic studies, human clinical trials, and population-based epidemiology studies, has highlighted the heterogeneity of the HFpEF syndrome, and has improved the understanding of the risk factors, pathogenesis, and pathophysiology of HFpEF. Dr. Shah has served as the international principal investigator, executive committee member, or steering committee member for >35 multicenter randomized clinical trials and studies in heart failure. He has published >450 peer-reviewed scientific publications, a textbook on cardiovascular genetics, and handbooks on internal medicine and cardiovascular disease.

Dr. Scott D. Solomon is the Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, where he directs the Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory. His research interests have focused on cardiac structure and function following myocardial injury and heart failure, modifiers of risk and outcomes in heart failure, and cardiovascular imaging. He is a world-renowned clinical trialist, having led numerous phase 2 and phase 3 clinical trials in heart failure, including 30 the PARAGON-HF and DELIVER trials in heart failure with mildly reduced and preserved ejection fraction. He has published more than 950 peer-reviewed articles, three textbooks of echocardiography, and serves as Editor for Braunwald’s Heart Disease.

Dr. Svati Shah is a physician scientist and Vice-Chief of Translational Research in the Division of Cardiology, Department of Medicine, and a faculty member and Co-Director of Translational Research in the Duke Molecular Physiology Institute (DMPI) and Duke Clinical Research Institute (DCRI). Her research focus is on metabolic and genetic pathways of cardiometabolic diseases, integrating diverse genomic, metabolomic and proteomic techniques for identification of novel mechanisms of disease and biomarkers. Her multidisciplinary molecular epidemiology lab within the DMPI has quantitative and molecular components and leverages several large cardiovascular biorepositories on which she is PI or co-I to perform discovery studies using omics technologies, with subsequent functional validation for mechanistic insight. Dr. Shah also collaborates closely with the DCRI for biomarker discovery in biospecimens from clinical trials and she is the Duke PI for the Verily Project Baseline study. Dr. Shah is also Director of the Duke Adult Cardiovascular Genetics Clinic where she cares for patients and their families who have, or at risk of, cardiovascular genetic disorders. Her training includes receiving a M.H.S. in epidemiology from Johns Hopkins School of Public Health, a Master’s degree in Medical Genomics from Duke University

Dr. Yuan Luo is currently Associate Professor at Department of Preventive Medicine, at Feinberg School of Medicine in Northwestern University. He is Chief AI Officer at Clinical and Translational Sciences Institute (NUCATS) and Institute for Augmented Intelligence in Medicine. Dr. Luo earned his PhD degree from MIT EECS with a math minor. He is a Fellow of American Medical Informatics Association (AMIA). He won the American Medical Informatics Association (AMIA) New Investigator Award in 2020. Dr. Luo has been developing a novel suite of accurate, interpretable and generalizable models to integrate multi-modal health data (e.g., clinical and insurance claims data) for improving health care practice and advancing medical knowledge. He 25 has been leading major research initiatives with >$10M in grant support, and has published over 100 peer-reviewed papers. His publications appear in leading journals including Nature Medicine, JAMA, AJRCCM, Circulation: Heart Failure, JAMIA, JBI etc. He has published in and/or served as PC members for top AI and informatics conferences including AAAI, KDD, CVPR, ACL etc. He has also been invited to give more than 50 keynotes and guest lectures at many top universities, think tanks, societies, industry labs.